858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer
· financialpost.com
— Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated HR+/HER2- unresectable or metastatic breast cancer —
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Thanks for signing up!
A welcome email is on its way. If you don't see i...